

Federico Alberici

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3202899/publications.pdf>

Version: 2024-02-01

85
papers

3,220
citations

201674

27
h-index

155660

55
g-index

100
all docs

100
docs citations

100
times ranked

4689
citing authors

#	ARTICLE	IF	CITATIONS
1	A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. <i>Kidney International</i> , 2020, 97, 1083-1088.	5.2	314
2	Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. <i>Journal of Autoimmunity</i> , 2015, 57, 60-65.	6.5	245
3	Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. <i>Kidney International Reports</i> , 2020, 5, 580-585.	0.8	195
4	Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. <i>Lancet</i> , 2011, 378, 338-346.	13.7	189
5	A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. <i>Kidney International</i> , 2020, 98, 20-26.	5.2	188
6	IgG4 immune response in Churg-Strauss syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 390-393.	0.9	171
7	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.	12.8	160
8	Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. <i>Rheumatology</i> , 2015, 54, 1153-1160.	1.9	108
9	Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 972-982.	6.1	103
10	Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1440-1447.	0.9	97
11	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. <i>Rheumatology</i> , 2011, 50, 899-905.	1.9	89
12	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 283-294.	6.1	89
13	Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. <i>American Journal of Transplantation</i> , 2020, 20, 3019-3029.	4.7	81
14	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78
15	Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. <i>Blood</i> , 2015, 126, 1163-1171.	1.4	69
16	Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series. <i>Journal of Autoimmunity</i> , 2015, 57, 24-29.	6.5	66
17	Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon- γ (IFN- γ) in Operable Renal Cell Carcinoma (RCC). <i>Journal of Immunotherapy</i> , 2014, 37, 440-447.	2.4	61
18	PTPN22 R620W polymorphism in the ANCA-associated vasculitides. <i>Rheumatology</i> , 2012, 51, 805-812.	1.9	60

#	ARTICLE	IF	CITATIONS
19	Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1584-1586.	0.9	56
20	Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1077-1083.	0.9	49
21	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.9	47
22	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.8	39
23	Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial. <i>PLoS ONE</i> , 2017, 12, e0185880.	2.5	37
24	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	5.8	37
25	Impact of rituximab trials on the treatment of ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1151-1159.	0.7	36
26	Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. <i>Rheumatology</i> , 2015, 54, 2004-2009.	1.9	32
27	Lupus nephritis and B-cell targeting therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 951-962.	3.0	29
28	Chronic periaortitis associated with membranous nephropathy: clues to common pathogenetic mechanisms. <i>Clinical Nephrology</i> , 2010, 74, 485-490.	0.7	27
29	Update on ANCA-associated vasculitis: from biomarkers to therapy. <i>Journal of Nephrology</i> , 2019, 32, 871-882.	2.0	24
30	Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. <i>Rheumatology</i> , 2007, 47, 315-318.	1.9	23
31	Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. <i>Journal of Infection</i> , 2021, 82, e4-e7.	3.3	23
32	The role of analytical methods for the determination of trace elements in environmental biomonitors. <i>Microchemical Journal</i> , 2002, 73, 131-152.	4.5	22
33	Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 30 Suppl 1, i37-45.	0.7	22
34	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1684-1687.e10.	2.9	22
35	Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. <i>Arthritis and Rheumatology</i> , 2019, 71, 1670-1680.	5.6	22
36	Pneumocystis jirevcii and SARS-CoV-2 Co-Infection: A Common Feature in Transplant Recipients?. <i>Vaccines</i> , 2020, 8, 544.	4.4	21

#	ARTICLE	IF	CITATIONS
37	Variable Expressivity of HNF1B Nephropathy, From Renal Cysts and Diabetes to Medullary Sponge Kidney Through Tubulo-interstitial Kidney Disease. <i>Kidney International Reports</i> , 2020, 5, 2341-2350.	0.8	21
38	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churgâ€Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	6.7	19
39	FcÎ³-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1597-1599.e8.	2.9	18
40	A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1662-1665.	2.9	17
41	Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 332-340.	2.9	17
42	Genetics of ANCA-associated vasculitides: HLA and beyond. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S90-7.	0.8	17
43	Orofacial granulomatosis treated with low-level laser therapy: a case report. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 113, e25-e29.	0.4	16
44	Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Caseâ€Control Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1694-1702.	5.6	13
45	Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia. <i>Frontiers in Immunology</i> , 2022, 13, 789713.	4.8	13
46	Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-Î± in patients with renal cell carcinoma. <i>Medical Oncology</i> , 2009, 26, 38-44.	2.5	11
47	Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey. <i>Journal of Nephrology</i> , 2021, 34, 325-335.	2.0	11
48	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1758-1760.	0.7	11
49	Correspondence on â€Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohortâ€™. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e158-e158.	0.9	11
50	Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-Î± in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile. <i>Oncology</i> , 2009, 76, 69-76.	1.9	10
51	The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. <i>Vaccines</i> , 2022, 10, 663.	4.4	10
52	The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult. <i>Kidney International Reports</i> , 2022, 7, 1878-1886.	0.8	10
53	Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC). <i>Journal of Immunotherapy</i> , 2007, 30, 780-786.	2.4	9
54	FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2020, 59, 3563-3566.	1.9	8

#	ARTICLE	IF	CITATIONS
55	Management of patients on dialysis and with kidney transplant during COVID-19 coronavirus infection. <i>PoÅki</i> , 2020, 9, 117-120.	0.4	7
56	SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response. <i>Journal of Nephrology</i> , 2022, , 1.	2.0	7
57	Expanding the variability of the ADPKD-GANAB clinical phenotype inÂa family of Italian ancestry. <i>Journal of Nephrology</i> , 2021, , 1.	2.0	5
58	FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome. <i>Immunology Letters</i> , 2018, 193, 11-13.	2.5	4
59	OP0148â€...MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 94-95.	0.9	3
60	Lessons From the Clinic: ADPKD Genetic Test Unraveling Severe Phenotype, Intrafamilial Variability, and New, Rare Causing Genotype. <i>Kidney International Reports</i> , 2022, 7, 895-898.	0.8	3
61	Association of a polymorphism of the FcÎ³-receptor 2A (FCGR2A) gene with chronic periaortitis. <i>Clinical and Experimental Rheumatology</i> , 2018, 37, 222-226.	0.8	2
62	Long term follow up of patients who received repeat dose rituximab as maintenance therapy for ANCA associated vasculitis (AAV). <i>Presse Medicale</i> , 2013, 42, 775-776.	1.9	1
63	TO037CLINICAL PREDICTORS OF RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS: A EUROPEAN COHORT. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i77-i77.	0.7	1
64	Prevention of arterial thrombosis recurrence in anti-phospholipid syndrome: are anti-platelets the answer?. <i>Rheumatology</i> , 2019, 58, 935-936.	1.9	1
65	The Authors Reply. <i>Kidney International Reports</i> , 2020, 5, 1376.	0.8	1
66	P0248HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): A POSSIBLE CAUSE OF VENOUS THROMBOEMBOLISM IN ACTIVE SYSTEMIC VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
67	Methotrexate vs cyclophosphamide as maintenance therapy in severe eosinophilic granulomatosis with polyangiitis (Churg Strauss): A subanalysis of the powercime trial. <i>Presse Medicale</i> , 2013, 42, 696-697.	1.9	0
68	Methotrexate plus prednisone in patients with relapsing chronic periaortitis. <i>Presse Medicale</i> , 2013, 42, 720-721.	1.9	0
69	MO040ASSOCIATION OF A TNFSF13B (BAFF) REGULATORY REGION SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i45-i46.	0.7	0
70	MP204SLOWLY PROGRESSIVE GLOMERULONEPHRITIS IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS (AAV). <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii502-iii503.	0.7	0
71	Magnetic resonance imaging in central nervous system vasculitis in a patient affected by crioglobulin-negative hepatitis C virus infection: A likely correlation. <i>Neuroradiology Journal</i> , 2018, 31, 193-195.	1.2	0
72	FP165SLOWLY PROGRESSIVE ANCA-ASSOCIATED GLOMERULONEPHRITIS: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0

#	ARTICLE	IF	CITATIONS
73	185.â€fGENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. Rheumatology, 2019, 58, .	1.9	0
74	298.â€fRITUXIMAB FOR DIFFICULT-TO-TREAT CHRONIC PARIAORTITIS: A CASE-SERIES OF 20 PATIENTS. Rheumatology, 2019, 58, .	1.9	0
75	Editorial: â€œToward Precision Medicine in Vasculitisâ€• Frontiers in Immunology, 2020, 11, 616221.	4.8	0
76	P0346THE EFFECTS OF RITUXIMAB MAINTENANCE THERAPY ON LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
77	P0372RITUXIMAB IN IDIOPATHIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS OF THE ADULT: A MULTICENTRE RETROSPECTIVE SURVEY OF 31 PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
78	P0286B CELL REPOPULATION AFTER REMISSION INDUCTION WITH RITUXIMAB IN NEWLY DIAGNOSED PATIENTS WITH ANCA-ASSOCIATED VASCULITIS: DOES ONE SIZE FIT ALL?. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
79	P0366SAFETY OF STEROID THERAPY IN IGA NEPHROPATHY: THE CLINICAL EXPERIENCE OF 48 NEPHROLOGY UNITS IN ITALY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
80	P0280ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. A CASE-CONTROL STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
81	MO040LONG-TERM FOLLOW-UP OF IGA NEPHROPATHY PATIENTS AT HIGH RISK OF PROGRESSION ACCORDING TO THE THERAPEUTIC APPROACH EMPLOYED: A MULTICENTER RETROSPECTIVE STUDY OF 947 PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
82	MO245OUTCOME OF DIFFERENT INDUCTION REGIMENS IN ANCA-ASSOCIATED GLOMERULONEPHRITIS ACCORDING TO THE HISTOPATHOLOGICAL CHARACTERISTICS: THE REASSESS STUDY*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
83	Genetics of ANCA-Associated Vasculitis. Rare Diseases of the Immune System, 2020, , 19-32.	0.1	0
84	THU0249â€...CLINICAL FEATURES AND RENAL PROGNOSIS IN LUPUS NEPHRITIS PATIENTS UNDERGOING A REPEATED BIOPSY: RESULTS OF 103 RE-BIOPSIES IN 438 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 351.1-352.	0.9	0
85	Hemodialysis techniques and outcomes in patients with COVID-19: The Brescia experience. Clinical Nephrology, 2022, , .	0.7	0